|
Sai Parenteral's Ltd
|
|
cs@saiparenterals.com Website:https://www.saiparenterals.com
|
|
Initial public offer of 10,428,288 equity shares of face value of Rs. 5 each ("Equity Shares") of Sai Parenteral's Limited ("Company" or "Issuer") for cash at a price of Rs. 392 per equity share (Including a Share Premium of Rs. 387 Per Equity Share) ("Offer Price") aggregating to Rs. 408.79 Crore comprising a fresh issue of 7,270,408 equity shares of face value of Rs. 5 each aggregating to Rs. 285 Crore by the company ("Fresh Issue") and an offer for sale of 3,157,880 equity shares of face value of Rs. 5 each aggregating to Rs. 123.79 Crore ("Offered Shares") by investor selling shareholders (such sale, the "Offer For Sale", and together with the fresh issue, the"Offer"). The offer shall constitute 23.60% of the post-offer paid up equity share capital of the company.
Price Band: Rs. 392 per equity share of face value of Rs. 5 each.
The floor price is 78.40 times the face value of the equity shares.
Bids can be made for a minimum of 38 equity shares of face value of Rs. 5 each and in multiples of 38 equity shares of face value of Rs. 5 each thereafter.
|
|
|
|
|
|
|
Sai Parenteral's Ltd
|
| |
Rs Cr |
Lead Managers to the Issue |
| 256.50 |
| Arihant Capital Markets Limited |
|
| 408.79 |
|
| 22.09 |
|
| Rs.
392.00
|
|
|
|
|
|
| Projects |
|
Capacity expansion and upgradation of manufacturing facilities
|
Establishment of a new R&D Centre
|
|
Repayment / prepayment of certain outstanding borrowings
|
Working capital requirements
|
|
Investment in wholly owned subsidiary, Sai Parenterals Pte Limited (Singapore), in relation to the proposed acquisition of Noumed Pharmaceuticals Pty Limited (Australia)
|
General corporate purposes
|
|
|
| Anil Kumar Karusala |
| Vijitha Gorrepati |
| Karusala Aruna |
|
|
|
| |
|
|